Pelthos Therapeutics Inc. (PTHS) 股票分析

公司概述

Pelthos Therapeutics Inc. operates as a bio-pharmaceutical entity focused on the development and commercialization of therapeutic products designed to address unmet treatment burdens for patients. The company functions within the healthcare sector, specifically the biotechnology industry, which is characterized by high research and development costs and significant regulatory hurdles before products reach the market. According to the available data, the company has a market capitalization of $75.47 million, reported annual revenue of $16.80 million, and employs 92 individuals. These valuation and revenue figures indicate that Pelthos Therapeutics is a small-cap biotechnology firm, suggesting it is likely in a growth or early commercialization phase where revenue generation is still scaling relative to its asset base and operational footprint.

财务健康

The company reported trailing twelve-month revenue of $16.80 million, with a corresponding net income of $-43,319,000 and an EBITDA of $-29,123,000. The substantial gap between the positive revenue figure and the large negative net income reveals a cost structure where operating expenses, particularly research and development or general administrative costs, significantly exceed the gross profit generated from product sales. Free cash flow stands at $-24,652,500, indicating that the company is consuming cash to fund its operations and strategic initiatives rather than generating surplus liquidity from its core business activities. Analysis of the margins shows a gross margin of 68.9%, which reflects a favorable cost of goods sold structure typical for biotechnology products, yet this is offset by an operating margin of -127.8% and a profit margin of -257.9%, highlighting the intense expense burden preventing profitability at the current scale. The balance sheet displays $17.97 million in cash against $34.83 million in debt, resulting in a debt-to-equity ratio of 89.58, which characterizes the company as highly leveraged given the negative equity environment. Despite the high debt load, the current ratio of 2.06 suggests adequate short-term liquidity, as current assets are more than double current liabilities, providing a buffer for immediate obligations. Furthermore, the return on equity is -239.6% and the return on assets is -29.8%, metrics that reveal management is currently generating negative returns on both shareholder capital and the total asset base, a common characteristic in pre-profit biotechnology companies.

估值评估

The trailing P/E ratio is listed as N/A due to negative earnings, while the forward P/E is -52.30, implying that the market is pricing in expectations of future profitability that are not yet reflected in current trailing earnings. The price-to-book ratio stands at 1.87, indicating that the market values the company's equity at a premium of 87% over its book value, a valuation often seen in firms with intangible assets like patents and pipeline potential. Alternative valuation metrics such as the price-to-sales ratio of 4.49 and an EV/EBITDA of -3.17 suggest that investors are valuing the company primarily on its revenue potential rather than current profitability or earnings power. The stock has traded between a 52-week high of $54.29 and a 52-week low of $9.00, meaning the current price sits significantly below the recent high, reflecting the volatility and risk premium associated with small-cap biotechnology stocks. The beta value of 3.94 indicates that the stock is highly sensitive to market movements, exhibiting nearly four times the volatility of the broader market index.

Growth & Income

Revenue growth and earnings growth rates are listed as N/A, which precludes a direct comparison of earnings expansion versus revenue expansion within the provided dataset. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute cash to shareholders and instead retains earnings to fund research, development, and commercialization efforts. This reinvestment strategy is standard for biotechnology companies that prioritize growing their product pipeline and expanding market presence over providing current income to investors. Consequently, the overall growth and income profile is defined by a complete reliance on capital appreciation potential and future product milestones rather than dividends or current earnings growth, with the financial data reflecting a capital-intensive growth model.